

Gesamtbericht

52. Durchgang des Rundversuches **Hormone**

Wien, am 20.10.2021

Sehr geehrte Frau Kollegin, sehr geehrter Herr Kollege,

bei dem 52. Durchgang des Rundversuches Hormone wurde die Probenverteilung am 28.09.2021 gestartet. Die Rücksendefrist endete am 10.10.2021. Die statistische Berechnung erfolgte am 20.10.2021.

Folgende Proben wurden ausgesandt:

| Probenoption | Bezeichnung | Hersteller |
|--------------|---------------------------------|------------|
| A | HM 401 62, HP 463 61, SD 060 18 | RfB |
| B | HM 401 64, HP 463 64, SD 060 19 | RfB |

Erläuterungen zu den Tabellenspalten

| | |
|-------|------------------------------------|
| Probe | jeweilige Probe |
| AnzE | Anzahl der eingelangten Ergebnisse |

Metrische Resultate

| | |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Kollektiv | Methodenkollektiv dem die von Teilnehmern übermittelten Ergebnisse zugeordnet wurden |
| * | Kollektiv ohne Bewertung (da die Anzahl der eingegangenen Teilnehmerergebnisse weniger als 6 oder Anzahl der Ergebnisse innerhalb der Akzeptanzgrenzen weniger als 5 ist); die Angabe der Ergebnisse hat nur informativen Charakter |
| Zielwert | der der Probe zugewiesene Wert in diesem Rundversuch [das für die Bestimmung des Zielwerts verwendete Ermittlungsverfahren] [a] Referenzwert [b] Konsenswert |
| %-Abw | tolerierte Abweichung vom Zielwert in % |
| AGrenzen | Akzeptanzintervall |
| Innerhalb | Anzahl und Anteil der Ergebnisse, die innerhalb des Akzeptanzintervalls liegen |
| Außerhalb | Anzahl und Anteil der Ergebnisse, die außerhalb des Akzeptanzintervalls liegen |
| MW | Mittelwert |
| Median | Median |
| SD | Standardabweichung |
| VK | Variationskoeffizient |

Nominale Resultate

| | |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Angabe | von Teilnehmern übermittelte Angaben |
| Referenz | das der Probe zugewiesene Ergebnis in diesem Rundversuch [das für die Bestimmung der Referenz verwendete Ermittlungsverfahren] [a] Referenzwert [b] Konsenswert |
| Anteil | Anzahl und Anteil der Ergebnisse die der Referenz entsprechen |



Es wurden folgende Ergebnisse erzielt:

LH mU/ml


Split: Methode

| Kollektiv | Probe | AnzE | Zielwert | %-Abw | AGrenzen | Korrekt | Außerhalb | MW | Median | SD | VK % |
|-----------------------|-------|------|------------|-------|------------------|-----------|-----------|--------|--------|-----|------|
| *alle* | A | 80 | 74.5 [b] | 15 | [63.3...85.7] | 69 (86%) | 11 (14%) | 74.5 | 76.0 | 5.9 | 7.93 |
| | B | 80 | 14.8 [b] | 15 | [12.6...17.0] | 55 (69%) | 25 (31%) | 14.8 | 15.4 | 1.3 | 8.69 |
| CMIA | A | 19 | 63.0 [b] | 15 | [53.6...72.5] | 19 (100%) | 0 (0%) | 63.0 | 63.5 | 2.1 | 3.30 |
| | B | 19 | 11.7 [b] | 15 | [10.0...13.5] | 18 (95%) | 1 (5%) | 11.7 | 11.8 | 0.4 | 3.44 |
| ECLIA | A | 52 | 78.0 [b] | 15 | [66.3...89.7] | 52 (100%) | 0 (0%) | 78.0 | 78.0 | 3.4 | 4.39 |
| | B | 52 | 15.8 [b] | 15 | [13.4...18.2] | 50 (96%) | 2 (4%) | 15.8 | 15.7 | 0.7 | 4.16 |
| LIA/Atellica Solution | A | 6 | 73.2 [b] | 15 | [62.2...84.2] | 6 (100%) | 0 (0%) | 73.2 | 73.0 | 2.1 | 2.88 |
| | B | 6 | 13.4 [b] | 15 | [11.4...15.4] | 6 (100%) | 0 (0%) | 13.4 | 13.3 | 1.1 | 7.88 |
| LIA/DxI 800 | A | 2 | 58.0 [b]* | 15* | [49.3...66.7]* | 2 (100%)* | 0 (0%)* | 58.0* | 58.0* | * | * |
| | B | 2 | 11.0 [b]* | 15* | [9.4...12.7]* | 2 (100%)* | 0 (0%)* | 11.1* | 11.1* | * | * |
| LIA/Immulate | A | 1 | 123.0 [b]* | 15* | [104.6...141.4]* | 1 (100%)* | 0 (0%)* | 123.0* | 123.0* | * | * |
| | B | 1 | 20.7 [b]* | 15* | [17.6...23.8]* | 1 (100%)* | 0 (0%)* | 20.7* | 20.7* | * | * |

S-Kurven aller Proben



Youden-Plots aller Probenpaare





● CMIA ■ ECLIA ▼ LIA/Atellica Solution ◆ LIA/Dxl 800 ▲ LIA/Immulite
 ● *alle*

FSH mU/ml


Split: Methode

| Kollektiv | Probe | AnzE | Zielwert | %-Abw | AGrenzen | Korrekt | Außerhalb | MW | Median | SD | VK % |
|-----------------------|-------|------|-----------|-------|----------------|-----------|-----------|-------|--------|-----|------|
| *alle* | A | 77 | 33.5 [b] | 15 | [28.5...38.5] | 70 (91%) | 7 (9%) | 33.5 | 33.5 | 2.1 | 6.31 |
| | B | 77 | 9.6 [b] | 15 | [8.2...11.1] | 70 (91%) | 7 (9%) | 9.6 | 9.7 | 0.5 | 5.66 |
| CMIA | A | 19 | 34.2 [b] | 15 | [29.1...39.4] | 19 (100%) | 0 (0%) | 34.2 | 34.3 | 2.0 | 5.77 |
| | B | 19 | 9.7 [b] | 15 | [8.3...11.2] | 19 (100%) | 0 (0%) | 9.7 | 9.8 | 0.4 | 4.60 |
| ECLIA | A | 49 | 33.2 [b] | 15 | [28.2...38.2] | 49 (100%) | 0 (0%) | 33.2 | 33.0 | 1.6 | 4.91 |
| | B | 49 | 9.6 [b] | 15 | [8.1...11.0] | 48 (98%) | 1 (2%) | 9.6 | 9.6 | 0.5 | 4.86 |
| LIA/Atellica Solution | A | 6 | 47.1 [b] | 15 | [40.0...54.1] | 6 (100%) | 0 (0%) | 47.1 | 47.8 | 3.2 | 6.84 |
| | B | 6 | 12.6 [b] | 15 | [10.7...14.5] | 6 (100%) | 0 (0%) | 12.6 | 12.8 | 0.4 | 3.34 |
| LIA/Dxl 800 | A | 2 | 32.2 [b]* | 15* | [27.4...37.1]* | 2 (100%)* | 0 (0%)* | 32.3* | 32.3* | * | * |
| | B | 2 | 9.8 [b]* | 15* | [8.4...11.3]* | 2 (100%)* | 0 (0%)* | 9.8* | 9.8* | * | * |
| LIA/Immulite | A | 1 | 41.5 [b]* | 15* | [35.3...47.7]* | 1 (100%)* | 0 (0%)* | 41.5* | 41.5* | * | * |
| | B | 1 | 10.7 [b]* | 15* | [9.1...12.3]* | 1 (100%)* | 0 (0%)* | 10.7* | 10.7* | * | * |

S-Kurven aller Proben



Youden-Plots aller Probenpaare





Östradiol pg/ml


Split: Methode

| Kollektiv | Probe | AnzE | Zielwert | %-Abw | AGrenzen | Korrekt | Außerhalb | MW | Median | SD | VK % |
|-----------|-------|------|----------|-------|-------------|-----------|-----------|-----|--------|----|-------|
| *alle* | A | 77 | 66 [b] | 20 | [53...79] | 71 (92%) | 6 (8%) | 66 | 66 | 5 | 8.16 |
| | B | 78 | 94 [b] | 20 | [76...113] | 77 (99%) | 1 (1%) | 94 | 94 | 7 | 6.90 |
| CMIA | A | 17 | 70 [b] | 20 | [56...84] | 13 (76%) | 4 (24%) | 70 | 68 | 11 | 15.31 |
| | B | 18 | 93 [b] | 20 | [75...112] | 17 (94%) | 1 (6%) | 93 | 92 | 7 | 8.03 |
| ECLIA | A | 50 | 65 [b] | 20 | [52...79] | 49 (98%) | 1 (2%) | 65 | 66 | 5 | 6.99 |
| | B | 50 | 95 [b] | 20 | [76...114] | 50 (100%) | 0 (0%) | 95 | 94 | 6 | 6.49 |
| ELFA | A | 2 | 55 [b]* | 20* | [44...66]* | 2 (100%)* | 0 (0%)* | 55* | 55* | * | * |
| | B | 2 | 92 [b]* | 20* | [73...110]* | 2 (100%)* | 0 (0%)* | 92* | 92* | * | * |
| LIA | A | 8 | 66 [b] | 20 | [53...79] | 8 (100%) | 0 (0%) | 66 | 66 | 5 | 7.57 |
| | B | 8 | 96 [b] | 20 | [77...115] | 8 (100%) | 0 (0%) | 96 | 96 | 10 | 10.14 |

S-Kurven aller Proben



Youden-Plots aller Probenpaare





Progesteron ng/ml


Split: Methode

| Kollektiv | Probe | AnzE | Zielwert | %-Abw | AGrenzen | Korrekt | Außerhalb | MW | Median | SD | VK % |
|-----------|-------|------|----------|-------|--------------|-----------|-----------|------|--------|-----|-------|
| *alle* | A | 79 | 1.8 [b] | 20 | [1.5...2.2] | 73 (92%) | 6 (8%) | 1.8 | 1.9 | 0.2 | 10.51 |
| | B | 79 | 11.1 [b] | 20 | [8.9...13.4] | 75 (95%) | 4 (5%) | 11.1 | 11.4 | 1.0 | 8.60 |
| CMIA | A | 19 | 1.7 [b] | 20 | [1.3...2.0] | 18 (95%) | 1 (5%) | 1.7 | 1.7 | 0.1 | 8.48 |
| | B | 19 | 10.0 [b] | 20 | [8.0...12.0] | 18 (95%) | 1 (5%) | 10.0 | 9.8 | 0.9 | 9.32 |
| ECLIA | A | 50 | 1.9 [b] | 20 | [1.5...2.3] | 49 (98%) | 1 (2%) | 1.9 | 1.9 | 0.1 | 7.40 |
| | B | 50 | 11.8 [b] | 20 | [9.4...14.1] | 50 (100%) | 0 (0%) | 11.8 | 11.8 | 0.5 | 3.83 |
| LIA | A | 10 | 1.7 [b] | 20 | [1.4...2.1] | 10 (100%) | 0 (0%) | 1.7 | 1.7 | 0.2 | 9.95 |
| | B | 10 | 8.9 [b] | 20 | [7.2...10.7] | 10 (100%) | 0 (0%) | 8.9 | 8.9 | 0.2 | 1.93 |

S-Kurven aller Proben



Youden-Plots aller Probenpaare





Testosteron ng/ml


Split: Methode

| Kollektiv | Probe | AnzE | Zielwert | %-Abw | AGrenzen | Korrekt | Außerhalb | MW | Median | SD | VK % |
|-----------|-------|------|-----------|-------|-----------------|-----------|-----------|-------|--------|------|------|
| *alle* | A | 66 | 14.67 [b] | 20 | [11.74...17.61] | 62 (94%) | 4 (6%) | 14.67 | 14.66 | 1.23 | 8.40 |
| | B | 67 | 1.60 [b] | 20 | [1.28...1.92] | 66 (99%) | 1 (1%) | 1.60 | 1.60 | 0.11 | 7.14 |
| CMIA | A | 16 | 16.20 [b] | 20 | [12.96...19.44] | 15 (94%) | 1 (6%) | 16.20 | 16.32 | 1.19 | 7.33 |
| | B | 17 | 1.53 [b] | 20 | [1.22...1.84] | 16 (94%) | 1 (6%) | 1.53 | 1.54 | 0.12 | 7.83 |
| ECLIA | A | 42 | 14.42 [b] | 20 | [11.54...17.31] | 40 (95%) | 2 (5%) | 14.42 | 14.62 | 0.71 | 4.92 |
| | B | 42 | 1.64 [b] | 20 | [1.31...1.96] | 42 (100%) | 0 (0%) | 1.64 | 1.64 | 0.09 | 5.47 |
| LIA | A | 8 | 12.75 [b] | 20 | [10.20...15.29] | 8 (100%) | 0 (0%) | 12.75 | 12.59 | 1.07 | 8.36 |
| | B | 8 | 1.50 [b] | 20 | [1.20...1.80] | 8 (100%) | 0 (0%) | 1.50 | 1.46 | 0.14 | 9.61 |

S-Kurven aller Proben



Youden-Plots aller Probenpaare




DHEAS µg/ml


Split: Methode

| Kollektiv | Probe | AnzE | Zielwert | %-Abw | AGrenzen | Korrekt | Außerhalb | MW | Median | SD | VK % |
|-----------|-------|------|----------|-------|---------------|-----------|-----------|------|--------|------|-------|
| *alle* | A | 49 | 2.93 [b] | 20 | [2.35...3.52] | 42 (86%) | 7 (14%) | 2.93 | 3.02 | 0.41 | 14.04 |
| | B | 49 | 3.97 [b] | 20 | [3.17...4.76] | 44 (90%) | 5 (10%) | 3.97 | 4.09 | 0.50 | 12.57 |
| CMIA | A | 11 | 2.62 [b] | 20 | [2.10...3.15] | 10 (91%) | 1 (9%) | 2.63 | 2.60 | 0.16 | 5.95 |
| | B | 11 | 3.68 [b] | 20 | [2.94...4.41] | 10 (91%) | 1 (9%) | 3.68 | 3.60 | 0.13 | 3.44 |
| ECLIA | A | 30 | 3.15 [b] | 20 | [2.52...3.78] | 30 (100%) | 0 (0%) | 3.15 | 3.13 | 0.19 | 6.00 |
| | B | 30 | 4.25 [b] | 20 | [3.40...5.10] | 30 (100%) | 0 (0%) | 4.25 | 4.25 | 0.25 | 5.80 |
| LIA | A | 8 | 2.34 [b] | 20 | [1.87...2.81] | 8 (100%) | 0 (0%) | 2.34 | 2.35 | 0.26 | 10.90 |
| | B | 8 | 3.23 [b] | 20 | [2.58...3.87] | 7 (88%) | 1 (12%) | 3.23 | 3.28 | 0.23 | 7.10 |

S-Kurven aller Proben



Youden-Plots aller Probenpaare





Prolactin ng/ml


Split: Methode

| Kollektiv | Probe | AnzE | Zielwert | %-Abw | AGrenzen | Korrekt | Außerhalb | MW | Median | SD | VK % |
|-----------|-------|------|----------|-------|---------------|-----------|-----------|------|--------|-----|------|
| *alle* | A | 77 | 8.7 [b] | 15 | [7.4...10.0] | 67 (87%) | 10 (13%) | 8.7 | 8.8 | 0.7 | 8.06 |
| | B | 77 | 36.9 [b] | 15 | [31.3...42.4] | 71 (92%) | 6 (8%) | 36.9 | 36.9 | 2.5 | 6.74 |
| CMIA | A | 18 | 8.2 [b] | 15 | [7.0...9.5] | 18 (100%) | 0 (0%) | 8.2 | 8.1 | 0.4 | 5.28 |
| | B | 18 | 36.8 [b] | 15 | [31.3...42.3] | 17 (94%) | 1 (6%) | 36.8 | 36.6 | 3.2 | 8.61 |
| ECLIA | A | 50 | 9.0 [b] | 15 | [7.6...10.3] | 48 (96%) | 2 (4%) | 9.0 | 9.0 | 0.4 | 4.59 |
| | B | 50 | 37.6 [b] | 15 | [32.0...43.2] | 49 (98%) | 1 (2%) | 37.6 | 37.4 | 1.7 | 4.49 |
| LIA | A | 9 | 6.7 [b] | 15 | [5.7...7.7] | 9 (100%) | 0 (0%) | 6.7 | 6.6 | 0.4 | 5.36 |
| | B | 9 | 31.8 [b] | 15 | [27.0...36.6] | 9 (100%) | 0 (0%) | 31.8 | 31.8 | 1.4 | 4.34 |

S-Kurven aller Proben



Youden-Plots aller Probenpaare





hCGβ U/I


Split: Methode

| Kollektiv | Probe | Anz E | Zielwert | %-Abw | AGrenzen | Korrekt | Außerhalb | MW | Median | SD | VK % |
|-----------------------|-------|-------|-------------|-------|--------------------|-----------|-----------|---------|---------|-----------|--------|
| *alle* | A | 108 | 10248 [b] | 20 | [8199...12298] | 92 (85%) | 16 (15%) | 10248 | 10431 | 1554 | 15.16 |
| | B | 108 | 92851 [b] | 20 | [74281...111421] | 86 (80%) | 22 (20%) | 92851 | 94692 | 1381 2 | 14.88 |
| CMIA | A | 29 | 9150 [b] | 20 | [7320...10981] | 28 (97%) | 1 (3%) | 9150 | 9063 | 411 | 4.49 |
| | B | 29 | 82431 [b] | 20 | [65945...98918] | 28 (97%) | 1 (3%) | 82431 | 82508 | 3852 | 4.67 |
| ECLIA stat Cobas 6000 | A | 4 | 8854 [b]* | 20* | [7083...10625]* | 3 (75%)* | 1 (25%)* | 8854* | 9163* | 932* | 10.53* |
| | B | 4 | 77859 [b]* | 20* | [62287...93431]* | 4 (100%)* | 0 (0%)* | 77859* | 79198* | 6038* | 7.76* |
| ECLIA/Cobas 6000 | A | 62 | 11279 [b] | 20 | [9023...13535] | 60 (97%) | 2 (3%) | 11279 | 11266 | 872 | 7.73 |
| | B | 62 | 102685 [b] | 20 | [82148...123222] | 59 (95%) | 3 (5%) | 102685 | 102283 | 6765 | 6.59 |
| ELFA | A | 1 | 14328 [b]* | 20* | [11462...17194]* | 1 (100%)* | 0 (0%)* | 14328* | 14328* | * | * |
| | B | 1 | 125495 [b]* | 20* | [100396...150000]* | 1 (100%)* | 0 (0%)* | 125495* | 125495* | * | * |
| LIA | A | 12 | 8020 [b] | 20 | [6416...9624] | 10 (83%) | 2 (17%) | 8020 | 8191 | 1116 | 13.92 |
| | B | 12 | 71657 [b] | 20 | [57326...85989] | 12 (100%) | 0 (0%) | 71657 | 72037 | 5208 | 7.27 |

S-Kurven aller Proben



Youden-Plots aller Probenpaare





Insulin $\mu\text{U/ml}$


Split: Methode

| Kollektiv | Probe | AnzE | Zielwert | %-Abw | AGrenzen | Korrekt | Außerhalb | MW | Median | SD | VK % |
|----------------|-------|------|------------|-------|------------------|-----------|-----------|--------|--------|-----|------|
| *alle* | A | 39 | 23.8 [b] | 15 | [20.2...27.3] | 28 (72%) | 11 (28%) | 23.8 | 23.6 | 1.6 | 6.73 |
| | B | 39 | 112.7 [b] | 15 | [95.8...129.6] | 29 (74%) | 10 (26%) | 112.7 | 112.0 | 6.7 | 5.90 |
| CMIA | A | 9 | 16.8 [b] | 15 | [14.3...19.3] | 9 (100%) | 0 (0%) | 16.8 | 16.6 | 0.9 | 5.29 |
| | B | 9 | 82.9 [b] | 15 | [70.5...95.3] | 9 (100%) | 0 (0%) | 82.9 | 82.4 | 3.0 | 3.66 |
| ECLIA | A | 29 | 23.8 [b] | 15 | [20.2...27.4] | 28 (97%) | 1 (3%) | 23.8 | 23.8 | 0.9 | 3.66 |
| | B | 29 | 112.9 [b] | 15 | [95.9...129.8] | 29 (100%) | 0 (0%) | 112.9 | 113.0 | 4.1 | 3.66 |
| LIA/Liaison XL | A | 1 | 30.2 [b]* | 15* | [25.7...34.7]* | 1 (100%)* | 0 (0%)* | 30.2* | 30.2* | * | * |
| | B | 1 | 137.2 [b]* | 15* | [116.6...157.8]* | 1 (100%)* | 0 (0%)* | 137.2* | 137.2* | * | * |

S-Kurven aller Proben



Youden-Plots aller Probenpaare





Cortisol µg/l


Split: Methode

| Kollektiv | Probe | AnzE | Zielwert | %-Abw | AGrenzen | Korrekt | Außerhalb | MW | Median | SD | VK % |
|-----------------------|-------|------|----------|-------|--------------|-----------|-----------|------|--------|----|------|
| *alle* | A | 52 | 124 [b] | 15 | [105...143] | 47 (90%) | 5 (10%) | 124 | 124 | 8 | 6.77 |
| | B | 52 | 115 [b] | 15 | [98...132] | 47 (90%) | 5 (10%) | 115 | 115 | 10 | 9.04 |
| CMIA | A | 17 | 118 [b] | 15 | [100...136] | 15 (88%) | 2 (12%) | 118 | 118 | 4 | 3.79 |
| | B | 17 | 106 [b] | 15 | [90...122] | 16 (94%) | 1 (6%) | 106 | 106 | 4 | 3.45 |
| ECLIA | A | 32 | 127 [b] | 15 | [108...146] | 31 (97%) | 1 (3%) | 127 | 127 | 6 | 4.93 |
| | B | 32 | 119 [b] | 15 | [101...137] | 31 (97%) | 1 (3%) | 119 | 118 | 7 | 5.84 |
| LIA/Atellica Solution | A | 2 | 160 [b]* | 15* | [136...184]* | 2 (100%)* | 0 (0%)* | 160* | 160* | * | * |
| | B | 2 | 138 [b]* | 15* | [117...158]* | 2 (100%)* | 0 (0%)* | 138* | 138* | * | * |
| LIA/Dxl 800 | A | 1 | 122 [b]* | 15* | [104...140]* | 1 (100%)* | 0 (0%)* | 122* | 122* | * | * |
| | B | 1 | 97 [b]* | 15* | [82...112]* | 1 (100%)* | 0 (0%)* | 97* | 97* | * | * |

S-Kurven aller Proben



Youden-Plots aller Probenpaare




Parathormon pg/ml


Split: Methode

| Kollektiv | Probe | AnzE | Zielwert | %-Abw | AGrenzen | Korrekt | Außerhalb | MW | Median | SD | VK % |
|-------------------------|-------|------|------------|-------|------------------|-----------|-----------|--------|--------|------|-------|
| *alle* | A | 78 | 11.3 [b] | 20 | [9.0...13.6] | 49 (63%) | 29 (37%) | 11.3 | 11.2 | 2.3 | 20.29 |
| | B | 78 | 102.4 [b] | 20 | [81.9...122.9] | 58 (74%) | 20 (26%) | 102.4 | 102.0 | 11.4 | 11.16 |
| CMIA | A | 14 | 16.1 [b] | 20 | [12.9...19.3] | 14 (100%) | 0 (0%) | 16.1 | 16.1 | 1.9 | 11.73 |
| | B | 14 | 165.1 [b] | 20 | [132.1...198.2] | 14 (100%) | 0 (0%) | 165.1 | 168.9 | 12.7 | 7.70 |
| ECLIA | A | 53 | 11.2 [b] | 20 | [8.9...13.4] | 49 (92%) | 4 (8%) | 11.2 | 11.2 | 1.1 | 9.82 |
| | B | 53 | 98.8 [b] | 20 | [79.1...118.6] | 52 (98%) | 1 (2%) | 98.8 | 98.2 | 5.3 | 5.40 |
| LIA/Access i-PTH | A | 2 | 8.2 [b]* | 20* | [6.5...9.8]* | 2 (100%)* | 0 (0%)* | 8.2* | 8.2* | * | * |
| | B | 2 | 116.6 [b]* | 20* | [93.2...139.9]* | 2 (100%)* | 0 (0%)* | 116.5* | 116.5* | * | * |
| LIA/Atellica PTH intact | A | 7 | 5.4 [b] | 20 | [4.3...6.5] | 7 (100%) | 0 (0%) | 5.4 | 5.3 | 0.6 | 10.43 |
| | B | 7 | 121.4 [b] | 20 | [97.1...145.7] | 7 (100%) | 0 (0%) | 121.4 | 122.0 | 13.6 | 11.19 |
| LIA/Liaison XL | A | 1 | 6.6 [b]* | 20* | [5.3...7.9]* | 1 (100%)* | 0 (0%)* | 6.6* | 6.6* | * | * |
| | B | 1 | 136.0 [b]* | 20* | [108.8...163.2]* | 1 (100%)* | 0 (0%)* | 136.0* | 136.0* | * | * |
| Tosoh AIA-360 | A | 1 | 7.8 [b]* | 20* | [6.2...9.4]* | 1 (100%)* | 0 (0%)* | 7.8* | 7.8* | * | * |
| | B | 1 | 125.0 [b]* | 20* | [100.0...150.0]* | 1 (100%)* | 0 (0%)* | 125.0* | 125.0* | * | * |

S-Kurven aller Proben



Youden-Plots aller Probenpaare



Vergleichbarkeitsklassen (Kollektive)

LH mU/ml

| Nummer | Kollektiv | Attribut | Ausprägung |
|--------|-----------------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | CMIA | Methode | CMIA/Alinity CMIA/Architect i2000 |
| 2 | ECLIA | Methode | ECLIA-2010 ECLIA/Cobas 6000 ECLIA/Cobas 8000 ECLIA/Cobas 8000-e801 ECLIA/Cobas e 411 ECLIA/Cobas e 601 ECLIA/Cobas pro ECLIA/Modular ELFA |
| 3 | LIA/Atellica Solution | Methode | LIA/Atellica Solution LIA/Centaur XP |
| 4 | LIA/Dxl 800 | Methode | LIA/Dxl 800 |
| 5 | LIA/Immulite | Methode | LIA/Immulite |

FSH mU/ml

| Nummer | Kollektiv | Attribut | Ausprägung |
|--------|-----------------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | CMIA | Methode | CMIA/Alinity CMIA/Architect i2000 |
| 2 | ECLIA | Methode | ECLIA-2010 ECLIA/Cobas 6000 ECLIA/Cobas 8000 ECLIA/Cobas 8000-e801 ECLIA/Cobas e 411 ECLIA/Cobas e 601 ECLIA/Cobas pro ECLIA/Modular |
| 3 | LIA/Atellica Solution | Methode | LIA/Atellica Solution LIA/Centaur XP |
| 4 | LIA/Dxl 800 | Methode | LIA/Dxl 800 |
| 5 | LIA/Immulite | Methode | LIA/Immulite |

Östradiol pg/ml

| Nummer | Kollektiv | Attribut | Ausprägung |
|--------|-----------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | CMIA | Methode | CMIA/Alinity CMIA/Architect i2000 |
| 2 | ECLIA | Methode | ECLIA-2010 ECLIA/Cobas 6000 ECLIA/Cobas 8000 ECLIA/Cobas 8000-e801 ECLIA/Cobas e 411 ECLIA/Cobas e 601 ECLIA/Cobas pro ECLIA/Modular |
| 3 | ELFA | Methode | ELFA |
| 4 | LIA | Methode | LIA/Atellica Solution LIA/Centaur eE2 LIA/Centaur XP LIA/Dxl 800 |

Progesteron ng/ml

| Nummer | Kollektiv | Attribut | Ausprägung |
|--------|-----------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | CMIA | Methode | CMIA/Alinity CMIA/Architect i1000 CMIA/Architect i2000 |
| 2 | ECLIA | Methode | ECLIA/Cobas 6000 ECLIA/Cobas 8000 ECLIA/Cobas 8000-e801 ECLIA/Cobas e 411 ECLIA/Cobas e 601 ECLIA/Cobas pro ECLIA/Modular ELFA |
| 3 | LIA | Methode | LIA/Atellica Solution LIA/Centaur XP LIA/Dxl 800 LIA/Immulite |

Testosteron ng/ml

| Nummer | Kollektiv | Attribut | Ausprägung |
|--------|-----------|----------|---------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | CMIA | Methode | CMIA/Alinity CMIA/Architect i1000 CMIA/Architect i2000 |
| 2 | ECLIA | Methode | ECLIA/Cobas 6000 ECLIA/Cobas 8000 ECLIA/Cobas 8000-e801 ECLIA/Cobas e 411 ECLIA/Cobas e 601 ECLIA/Cobas pro ECLIA/Modular |
| 3 | LIA | Methode | HPLC/MS LIA/Atellica Solution LIA/Centaur XP LIA/Dxl 800 |

DHEAS µg/ml

| Nummer | Kollektiv | Attribut | Ausprägung |
|--------|-----------|----------|---------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | CMIA | Methode | CMIA/Alinity CMIA/Architect i2000 |
| 2 | ECLIA | Methode | ECLIA/Cobas 6000 ECLIA/Cobas 8000 ECLIA/Cobas 8000-e801 ECLIA/Cobas e 411 ECLIA/Cobas e 601 ECLIA/Cobas pro ECLIA/Modular |
| 3 | LIA | Methode | LIA/Atellica Solution LIA/Centaur XP LIA/Dxl 800 LIA/Immulin |

Prolactin ng/ml

| Nummer | Kollektiv | Attribut | Ausprägung |
|--------|-----------|----------|---------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | CMIA | Methode | CMIA/Alinity CMIA/Architect i2000 |
| 2 | ECLIA | Methode | ECLIA/Cobas 6000 ECLIA/Cobas 8000 ECLIA/Cobas 8000-e801 ECLIA/Cobas e 411 ECLIA/Cobas e 601 ECLIA/Cobas pro ECLIA/Modular |
| 3 | LIA | Methode | LIA/Atellica Solution LIA/Centaur XP LIA/Dxl 800 LIA/Immulin |

hCGB U/l

| Nummer | Kollektiv | Attribut | Ausprägung |
|--------|-----------------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | CMIA | Methode | CMIA stat/Architect i1000 CMIA stat/Architect i2000 CMIA/Alinity CMIA/Architect i1000 CMIA/Architect i2000 |
| 2 | ECLIA stat Cobas 6000 | Methode | ECLIA stat Cobas 6000 |
| 3 | ECLIA/Cobas 6000 | Methode | ECLIA stat Cobas 8000 ECLIA/Cobas 6000 ECLIA/Cobas 8000 ECLIA/Cobas 8000-e801 ECLIA/Cobas e 411 ECLIA/Cobas e 601 ECLIA/Cobas pro ECLIA/Modular |
| 4 | ELFA | Methode | ELFA |
| 5 | LIA | Methode | LIA/Atellica Solution LIA/Centaur XP LIA/Dxl 800 LOCI/Dimension VISTA |

Insulin $\mu\text{U/ml}$

| Nummer | Kollektiv | Attribut | Ausprägung |
|--------|----------------|----------|----------------------------------------------------------------------------------------------------------------------------|
| 1 | CMIA | Methode | CMIA/Alinity CMIA/Architect i1000 CMIA/Architect i2000 |
| | | | |
| 2 | ECLIA | Methode | ECLIA/Cobas 6000 ECLIA/Cobas 8000 ECLIA/Cobas 8000-e801 ECLIA/Cobas e 411 ECLIA/Cobas e 601 ECLIA/Cobas pro |
| | | | |
| 3 | LIA/Liaison XL | Methode | LIA/Liaison XL |

Cortisol $\mu\text{g/l}$

| Nummer | Kollektiv | Attribut | Ausprägung |
|--------|-----------------------|----------|---------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | CMIA | Methode | CMIA/Alinity CMIA/Architect i1000 CMIA/Architect i2000 |
| | | | |
| 2 | ECLIA | Methode | ECLIA/Cobas 6000 ECLIA/Cobas 8000 ECLIA/Cobas 8000-e801 ECLIA/Cobas e 411 ECLIA/Cobas e 601 ECLIA/Cobas pro ECLIA/Modular |
| | | | |
| 3 | LIA/Atellica Solution | Methode | LIA/Atellica Solution |
| | | | |
| 4 | LIA/Dxl 800 | Methode | LIA/Dxl 800 |

Parathormon pg/ml

| Nummer | Kollektiv | Attribut | Ausprägung |
|--------|-------------------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | CMIA | Methode | CMIA/Architect i4100 CMIA stat/Architect i1000 i-PTH CMIA/Alinity i-PTH CMIA/Architect i1000 i-PTH CMIA/Architect i2000 i-PTH |
| 2 | ECLIA | Methode | ECLIA-2010 PTH stat ECLIA/Cobas 6000 PTH ECLIA/Cobas 6000 PTH biointact ECLIA/Cobas 6000 PTH stat ECLIA/Cobas 8000 PTH ECLIA/Cobas 8000 PTH biointact ECLIA/Cobas 8000 PTH stat ECLIA/Cobas e411 PTH ECLIA/Cobas e411 PTH biointact ECLIA/Cobas e601 PTH ECLIA/Cobas e601 PTH biointact ECLIA/Cobas e801 PTH ECLIA/Cobas e801 PTH biointact ECLIA/Cobas e801 PTH stat ECLIA/Cobas pro PTH |
| 3 | LIA/Access i-PTH | Methode | LIA/Access i-PTH |
| 4 | LIA/Atellica PTH intact | Methode | CLIA/IDS LIA/Atellica PTH intact LIA/Centaur XP i-PTH |
| 5 | LIA/Liaison XL | Methode | LIA/Liaison XL |
| 6 | Tosoh AIA-360 | Methode | Tosoh AIA-360 |

Mit besten Grüßen

Dr. Christoph Buchta, MBA
Technische Leitung

Univ. Prof. Dr. Christian Bieglmayer
Versuchsleitung